Debiopharm and MSM to develop GPCR-targeting antibody for oncology
This article was originally published in Scrip
Executive Summary
Debiopharm, the Swiss biopharmaceutical group, and US drug discovery company MSM Protein Technologies, are to work together on a GPCR-targeting antibody programme known as Debio 0929 with the aim of developing a new oncology drug.